Maura McCarthy: Barriers to follow up from an abnormal clinical breast exam in UP, India

Maura McCarthy, Director of Global Oncology Policy and Advocacy at AstraZeneca, shared a post by Erica Liebermann on LinkedIn, adding:

“Very exciting to see these learnings on barriers to follow up from an abnormal clinical breast exam in early detection programming in UP, India published in American Society of Clinical Oncology (ASCO), JCO Global Oncology.

As attention turns towards strengthening patient navigation across health systems, these data support the need for gender responsive programming and transformative approaches.”

Quoting Erica Liebermann’s post on LinkedIn:

“I’m happy to share our paper published with the team at Jhpiego India from our qualitative study on barriers to follow-up for an abnormal clinical breast exam in UP, India.

Women continue to face knowledge, cultural, and health system barriers to diagnostic follow-up of an abnormal CBE in primary care settings. We need gender-responsive strategies to improve access to care and promote earlier diagnosis of breast cancer.”

“Barriers to Follow-Up of an Abnormal Clinical Breast Examination in Uttar Pradesh, India: A Qualitative Study”

Authors: Erica Liebermann, Vaibhav Patwardhan, Gulnoza Usmanova, Nadeem Aktar, Shivani Agrawal, Parag Bhamare, Maura McCarthy, Ophira Ginsburg, and Somesh Kumar.

Maura McCarthy is the Director of Global Oncology Policy and Advocacy at AstraZeneca. She previously worked at Jhpiego, where she served as the Women’s Cancer Team Lead. Additionally, she was a consultant for Pink Ribbon Red Ribbon.